Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC | Bioconjugates | Oncology/Cancer | Solid tumor | Preclinical | Global |
Her2xCD3 BsAb | Bispecific antibody | Oncology/Cancer | HER2-positive Cancer | Phase I | Global |
Expression analysis of human ErbB2 on HEK293/Human ErbB2 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ErbB2 Stable Cell Line or negative control cell using anti-human ErbB2 Antibody followed by staining with PE anti-human IgG Fc Antibody.
5e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Her2, His Tag (Cat. No. HE2-HA2H7) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
Trastuzumab Biosimilar captured on Protein A Chip can bind Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) with an affinity constant of 7.49 nM as determined in a SPR assay (Biacore 8K) (QC tested).
This web search service is supported by Google Inc.